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Viral infections contribute as a cause of 15–20% of all human cancers. Infection by oncogenic viruses can promote diﬀerent stages
of carcinogenesis. Among many types of HPV, around 15 are linked to cancer. In spite of eﬀective screening methods, cervical
cancer continues to be a major public health problem. +ere are wide diﬀerences in cervical cancer incidence and mortality by
geographic region. In addition, the age-speciﬁc HPV prevalence varies widely across diﬀerent populations and showed two peaks
of HPV positivity in younger and older women. +ere have been many studies worldwide on the epidemiology of HPV infection
and oncogenic properties due to diﬀerent HPV genotypes. However, there are still many countries where the population-based
prevalence has not yet been identiﬁed. Moreover, cervical cancer screening strategies are diﬀerent between countries. Organized
cervical screening programs are potentially more eﬀective than opportunistic screening programs. Nevertheless, screening
programs have consistently been associated with a reduction in cervical cancer incidence and mortality. Developed countries have
achieved such reduced incidence and mortality from cervical cancer over the past 40 years. +is is largely due to the imple-
mentation of organized cytological screening and vaccination programs. HPV vaccines are very eﬀective at preventing infection
and diseases related to the vaccine-speciﬁc genotypes in women with no evidence of past or current HPV infection. In spite of the
successful implementation of the HPV vaccination program in many countries all over the world, problems related to HPV
prevention and treatment of the related diseases will continue to persist in developing and underdeveloped countries.
1. Introduction
According to the World Health Organization’s (WHO) sta-
tistics, common cancers are one of the most prevalent causes
of mortality worldwide with 8.2 million deaths in 2012, and
this trend has not changed in recent years. Viral infections
contribute to 15–20% of all human cancers, whereby several
viruses play considerable roles in the multistage development
of malignant cancers. Over the past two decades, it has be-
come obvious that several viruses play an important role in
the development of human cancers. Around 15% to 20% of
cancer cases are associated with viral infections. Oncogenic
viruses can facilitate various stages of carcinogenesis [1]. One
of the viruses contributing to the statistics of cancerous
diseases is human papillomavirus (HPV). HPV is a virus that
can be sexually transmitted, and high-risk HPVDNA is found
to be present in 99.7% of cervical cancer specimens [2].
Within 12 to 24months of exposure to the virus, 90% of HPV
infections are cleared or become inactive. However, infections
by the high-risk HPV types persist which then increase the
risk of progression to cervical cancer [3].
HPV is a double-stranded DNA virus belonging to the
Papovaviridae family. Almost 200 HPV types have been
identiﬁed with more than 40 types colonizing the genital
tract. All HPV infection types are divided into two groups
based on their carcinogenic properties; these are high risk
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and low risk. High-risk types include 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 68, and 59. Others are classiﬁed as potential
high-risk (which are 53, 66, 70, 73, and 82). Currently, it is
well known and proven that HPV16 and 18 are the most
virulent high-risk genotypes, causing about 70% of all in-
vasive cervical cancer in the world [4].
At the present time, we have a relatively clear picture of
HPV infection’s natural history, oncogenic properties,
screening, and prevention algorithms. However, HPV in-
fection rates continue to persist, especially in developing
countries, where cervical cancer incidence and prevalence
are still high. +is is due to diﬀerent reasons, which include
low socioeconomic status, lack of population awareness, and
inadequately implemented screening and vaccination pro-
grams. +us, it is necessary to continue this discussion and
to refocus attention of specialists and population worldwide
to HPV infection and related diseases.+e aim of this review
article is to summarize updated information regarding the
aforementioned aspects of HPV infection and related can-
cers, including also discussions about the HPV genome and
molecular events leading to cancer development following
an HPV infection. Enhanced knowledge of HPV status and
cancer progression events contributes to the improvement of
the future management of patients with cervical lesions; this
in turn can help mitigate cervical cancer progression among
HPV-infected women.
2. The HPV Genome
Papillomavirus genome is comprised of a small double-
stranded and highly conserved DNA with an approximate
size of 8000 base pairs and consists of three regions. +e
molecular biology of this small DNA molecule is complex.
+ere are six early proteins, three regulatory proteins (E1,
E2, and E4) and three oncoproteins (E5, E6, and E7) encoded
in 4000 base pairs (bp) that participate in viral replication
and transformation of cell. Another 3000 bp region of DNA
molecule encodes two structural proteins L1 and L2 that
compose the capsid of virus. +e viral DNA replication and
transcriptional regulatory elements are controlled by a long
control region (LCR) that is encoded in a 1000 bp region [5].
Upon the viral evolution, accumulation of numerous
lineage-deﬁning genetic variations in these regions can lead
to speciation into separate HPV types. Sequence variations
such as single-nucleotide polymorphisms or genetic muta-
tions within L1, LCR, E6, and E7 regions of HPV can de-
termine families, relatedness, and phylogeny of the HPV
types. HPV type can be deﬁned as an entity based on the
more than 10% diﬀerence in the DNA sequence of the L1
gene between two genomes. However, the diﬀerence be-
tween 2% and 10% determines the HPV subtypes. In ad-
dition, the variants are entities that deﬁne less than 2% of
dissimilarities between HPV genomes. According to recent
studies, there are 60 out of 160 HPV types associated with
mucosal epithelia and categorized as Alphapapillomavirus
genus (alpha-PV) [6]. Furthermore, alpha-PV can be clas-
siﬁed into nine groups: alpha-5 (HPV23, 51, 69, and 82),
alpha-6 (HPV30, 53, 56, and 66), alpha-7 (HPV18, 39, 45, 59,
68, 70, 85, and 97), and alpha-9 (HPV16, 31, 33, 35, 52, 58,
and 67), which include mostly the oncogenic high-risk types
[7]. However, there are also Betapapillomavirus and Gam-
mapapillomavirus genus that have not been investigated in
detail yet [8].
According to Papillomavirus Nomenclature Committee,
each HPV type can be diﬀerentiated into phylogenetic
lineages in terms of geographic distribution, pathogenicity,
regulation of transcription, and immunological response [9].
+e alpha-9 HPV16 type has been further classiﬁed into four
phylogenetic lineages: A, B, C, and D. Phylogeny A is divided
further into four sublineages A1, A2, A3, and A4. Sub-
lineages A1, A2, and A3 include European HPV DNA se-
quences while A4 includes Asian sequences isolated
worldwide. Lineage B is classiﬁed as B1 and B2 sublineages,
which comprise the African HPV sequences. Lineage C is
also referred to as African sequences. Lineage D consists of 3
sublineages: D1, D2, and D3 that include Asian-American
and North American sequences. HPV intratypic molecular
variants can be distinguished based on oncogenic potentials
in spite of their phylogenetic relatedness. Several research
studies associate the HPV16 lineage D as being more tu-
morigenic in comparison with the other lineages [10].
3. Association between HPV Infection and
Cervical Lesions
+e vast majority of HPV infections are transitory and
become undetectable in 12–24months [4, 11–14]. However,
in some women whose infections continue to persist, the risk
of developing precancerous conditions is signiﬁcant. Many
studies conﬁrmed that persistent infection with an onco-
genic HPV type is themain risk factor for detecting a cervical
intraepithelial neoplasia (CIN) that may range from CIN1 to
CIN3 and cancer [12, 13, 15]. In the VIVIANE study, the
researchers found that HPV33 and HPV16 were associated
with the highest risk of CIN development, followed by
HPV18, HPV31, and HPV45 [13].
Natural history of CIN lesions is diﬀerent depending on
its grade. CIN1 is a low-grade squamous intraepithelial
lesion (LSIL). According to statistical data, over 70–80% of
CIN1 lesions spontaneously regress without treatment or
become undetectable [11, 16]. +us, CIN1 reﬂects a state of
infection rather than a stage in disease development. De-
tection of CIN1 following HPV infection does not therefore
automatically represent disease progression. Furthermore,
obvious clearance may be attributed to an inability to detect
the infection [13]. +erefore, clearance rates should be
interpreted with caution.
CIN2 and CIN3 are considered high-grade dysplasia or
high-grade squamous intraepithelial lesion (HSIL); however,
they are diﬀerent whereby CIN2 less commonly progresses
to cancer. CIN2 develops in two diﬀerent ways; the annual
regression rate of CIN2 in adult women is estimated to range
from 15 to 23%, with up to 55% regressing by 4–6 years
[16, 17], whereas approximately 2% of CIN2 lesions develop
to CIN3 within the same period. CIN3 is considered a true
precancer with the potential to progress to invasive cancer at
a rate of 0.2% to 4% within 12months [16, 18]. Untreated
CIN3 has a 30% probability of becoming invasive cancer
2 Journal of Oncology
over a 30-year period, although only about 1% of properly
treated CIN3 will become invasive [12, 16, 18, 19]. Ade-
nocarcinoma of the cervix is distinct from squamous cell
carcinoma as it arises from the glandular epithelium of the
endocervical canal and its immediate precursor is adeno-
carcinoma in situ. +e time from HPV infection to cervical
cancer development is typically 20 years; therefore, rapid
progression of cervical cancers rarely occurs [20].
+e link between high-risk HPV types and cervical cancer
development contributed to the introduction of novel screening
programs. For example, testing for the presence of high-risk
HPV is recommended as a screening tool by theWHO and the
European Guidelines for Quality Assurance for Cervical Cancer
Screening [21, 22]. HPV testing has been found to be eﬀective in
detection of precancerous cervical lesions particularly in pop-
ulation-based cervical screening programs [23]. +e establish-
ment of the causal link between HPV and cervical cancer, along
with an understanding of the epidemiology and natural history
of HPV infection, has led to a new model for cervical carci-
nogenesis: HPV acquisition, HPV persistence, progression to
precancer, and invasion [24], which helps guide age-appropriate
interventions to prevent cervical cancer.
4. Pathogenesis of Cervical Cancer
Development following HPV Infection
Cervical cancerogenesis can be deﬁned as the complex
mechanism of uncontrolled cellular division that can involve
HPV gene integration together with other cellular changes and
epigenetic factors. As the HPV infection occurs, the DNA can
undergomutations under the cellular and other environmental
conditions leading to viral DNA integration and operationwith
the hostDNA synthesismachinery. As a result, virus can escape
cellular and immune defensemechanisms while promoting cell
proliferation and inhibiting cellular apoptotic mechanisms.
Oncogenic potential of HPV16 depends on the regulation
of viral transcriptional factors. At the initiation of viral in-
fection, the HPV16 genome can be presented as unintegrated
small DNAmolecule also called episome and results in benign
and precancerous lesions of the cervix. However, HPV16 can
integrate its genome into the host genome, which in turn can
lead to the development of cervical carcinoma and cervical
intraepithelial neoplasia grade III [10]. Viral genome in-
tegration in combinationwith dysregulation of the E2 protein,
which is a repressor of the oncoprotein, contributes towards
the carcinogenic process. +ese events cause overexpression
of E6 and E7 proteins that eventually contribute to viral
carcinogenesis by altering cellular apoptotic mechanism
[5, 10]. Overexpression of E6 and E7 alone is insuﬃcient to
contribute to the cancerogenesis as other genetic and epi-
genetic factors also need to be established.
+ere are many types of HPV, which are found to be
associated with cancerous diseases—16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 68, 73, and 82 types [4]. +e most car-
cinogenic HPV type is HPV16, and 50% of all cervical
cancers are associated with HPV16 [15]. In HPV16-positive
cells, it is found that E6 and E7 viral genes are retained
integrated into the host genome and are expressed, although
in some HPV16-infected cells E6/E7 overexpression can be
absent. Moreover, E6/E7 overexpression is also found in
cells infected by other HPV types [25, 26]. E6 and E7 are
small proteins of 150 and 100 amino acids without any
known enzymatic activity, but they can inﬂuence the host
cell activity by binding with cellular proteins. E6, for ex-
ample, binds with E6-associated binding protein (E6AP), a
ubiquitin ligase leading to a structural change in E6 allowing
it to bind with p53, the cell cycle control tumor suppressor
protein to form a trimeric complex E6/E6AP/p53 (Figure 1).
+is binding leads to the degradation of p53 and thus
leads to cell proliferation. E7, on the other hand, binds pRb
causing its inactivation and degradation. Both the low-risk
and high-risk E7 protein has been shown to target the pRB
family members including p107 (RBL1) and p130 (RBL2) for
degradation [27]. pRb downregulates E2F a transcription
factor. As pRb is deactivated by E7, E2F is upregulated and
cell proliferation genes are activated. Furthermore, E6 and
E7 have been shown to form complexes with hundreds of
other proteins in the host cell [28–30] and it will be in-
teresting to understand the functions and consequence of
what these complexes do. It is important to note that E6 and
E7 transforming and oncogenic properties involve other
cancer pathways not involving p53 or pRB. For example, E7
stimulates telomerase activity [31] and E6/E7 has been
shown to deregulate miRNA linked to carcinogenesis [32].
E7 has also been shown to interact with histone deacetylase-
(HDAC1-3-) enhancing E2F activation that is associated
with diﬀerentiation and viral replication [33].
miRNA plays an important role in the posttranscriptional
control of the expression of host genes. Recent studies pro-
posed that HPV E6, E7, and E5 oncoproteins regulate the host
miRNA proﬁle. In HPV-associated cervical cancer cells, a
number of miRNAs such as miR-21, miR-143, and miR-9 are
overexpressed, thus targeting CCL20 (chemokine (C-C)motif
ligand) and promoting migration of HPV16-positive can-
cerous cells. However, overexpression of some miRNAs such
as miR-203 inhibits HPV ampliﬁcation. +us, in the HPV-
infected cancer cells, miR-203 is suppressed by HPV E7 gene
overexpression, leading to the induction of viral replication.
Deregulation of miRNA expression can occur mostly due to
epigenetic methylation of miRNA promoters [34].
E6 belonging to tumorigenic HPV types harbors a PDZ
binding motif (PBM) at the C terminus which facilitates the
binding of E6 to a number of proteins containing the PDZ
site. +e binding of E6 to these proteins leads to inactivation
and degradation. Examples of such proteins include po-
tential tumor suppressors such as Dlg [35], MAGI-1 [36],
and Scribble [37, 38].
+e epigenetic control of viral and host gene expression
plays an important role in carcinogenesis by involving changes
inDNAmethylation,modiﬁcations of histones, and noncoding
RNAproﬁle. Cervical carcinogenesis is strongly associated with
persistent HPV infection that can further aﬀect both the host
genome and the viral genome methylation process [34].
E6 and E7 have been shown to bind DNA methyl-
transferases (DNMT) which impairs their activity leading to
hypermethylation of CpG islands which can eventually lead
to possible silencing of host tumor suppressors [30, 39].
Some studies showed decreased methylation of the upstream
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regulatory region (URR) in the cervical cancer cells in
comparison with normal cells, whereas other studies de-
scribed increased methylation of the viral genome [40].
+ese studies’ discrepancies can be explained by the viral life
cycle stages, type of HPV genome integrations, cervical
cancer stages, and other factors. However, methylation of
viral DNA can be deﬁned as the host cellular defense
mechanism. So, it is still poorly investigated if HPV DNA
methylation is beneﬁcial for viral cancerogenesis [34].
It has been suggested that increased methylation of CpG
dinucleotides within E2 binding site (E2BS) on the host
genome canmodify interaction of diﬀerent factors and result
in abnormal cell diﬀerentiation with further disease pro-
gression [34]. As a result, this hypermethylation event re-
duces the binding aﬃnity of the viral regulatory protein E2
to E2BS, thus leading to E6 and E7 overexpression and
further epigenetic inhibition of tumor suppressor genes [10].
Some studies suggest that CpG region methylation can be
used as a biomarker of cervical cancer detection.
5. Epidemiology of Cervical Cancer
Cervical cancer is the leading genital cancer among women
worldwide, with almost half a million new cases per year
(GLOBOCAN, 2012) [41]. In 2015, 526,000 women developed
cervical cancer worldwide and caused 239,000 deaths [42].+e
majority of cervical cancer cases are squamous cell carcinoma
[41]. In spite of eﬀective screening methods, cervical cancer
continues to be a major public health problem [4].
+e mortality from cervical cancer varies in diﬀerent geo-
graphic regions.+e age-standardized incidence rate for cervical
cancer is much lower in developed countries at 5.0 per 100,000
compared to developing countries at 8.0 per 100,000 [43].
Similarly, the age-standardized mortality rate for cervical cancer
is lower in developed nations at 2.2 per 100,000 compared with
developing nations at 4.3 per 100,000. For example, in sub-
Saharan Africa, there were 34.8 new cases and 22.5 deaths per
100,000 women, while in Western Asia there were only 4.4 new
cases and 1.9 deaths per 100,000 women in 2012 [44]. In
comparison, Northern America is found to be the region with
the third-lowest cervical cancer rate in the world [43].
Limited statistical data are available on cervical cancer in
Central Asia [43]. From the existing sources, it is found that
the incidence rates of cervical cancer in many countries of
Central Asia are quite high (ranging from 9.9 per 100,000
women in Tajikistan to 29.4 per 100,000 in Kazakhstan)
compared to Europe (ranging from 4.0 per 100.000 in
Finland and 7.0 per 100.000 in Germany) [43–45]. Ap-
proximately 25,700 women are diagnosed with cervical
cancer and 12,700 die from this disease annually in the
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Figure 1: Progression of cervical cancerogenesis which involves HPV gene integration, leading to sustained expression of E6 and E7,
impacting and dysregulating the various pathways including the inactivation and degradation of p53 and pRB that lead to uncontrolled
cellular division, proliferation, tumor suppressor evasion, and other features of tumorigenicity.
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Central Asian countries [46]. +e mortality rates range from
4.9 per 100,000 women in Tajikistan to 11.2 per 100,000 in
Kyrgyzstan [41, 46]. +e indicators are higher than in
Western European countries (incidence rates ranging from
2.1 per 100,000 women in Malta to 12.2 per 100,000 in
Portugal; mortality rates ranging from 0.8 per 100,000
women in Iceland to 3.6 per 100,000 in Portugal) [46].
Cervical cancer has a bimodal age distribution with the
majority of cases occurring among women in their 30s and
40s, the age at which women are often raising families and
ensuring the ﬁnancial viability of their families and com-
munities. In addition to the risk of death, cervical cancer is
associated with increased morbidity, including bleeding,
pain, and kidney failure, which are diﬃcult to treat, espe-
cially in communities with poor access to healthcare [47].
6. Prevalence of HPV in the General Population
and in Cervical Cancer Patients
HPV infections are widespread all over the world; however,
prevalence and type distribution are heterogeneous [48].+e
age-speciﬁc HPV prevalence varies in young and advanced
age women populations [49]. A comprehensive meta-
analysis assessing the global prevalence of cervical HPV
infection among women without cervical lesions revealed
that almost 12% of females worldwide are positive for HPV
DNA [50].
+ere have been many studies worldwide on the epi-
demiology of HPV infection and oncogenic properties due
to diﬀerent HPV genotypes [4]. One of the international
studies found that 10.4% of patients with normal cytology
have been detected with either high- or low-risk HPV types.
Women in less developed countries and those who are
younger than 25 years old have a higher prevalence, ranging
from 15 to 45% [50]. +e highest HPV prevalence was
observed in sub-Saharan Africa (24%), Eastern Europe
(21.4%), and Latin America (16.1%) and the lowest in
Northern America (4.7%) and Western Asia (1.7%). +e
HPV type 16 was the most common virus worldwide with
prevalence rates accounting for 32.3% of all infections in
Southern Asia, 28.9% in Southern Europe, 24.4% inWestern
Europe, 24.3% in Northern America, and 12% in Africa [51].
According to the Extended Middle East and North
Africa (EMENA) study, in the Middle East, the incidence of
HPV shows lower rates compared to the rest of the world
[52]. For instance, in Qatar HPV prevalence among the
general population of women with normal or abnormal
cytology recently estimated 6.1% [52]. +e authors detected
the presence of various HPV genotypes with a high prev-
alence of low-risk HPV types, particularly type 81.
Very limited data are available on HPV prevalence,
incidence, and genotype-speciﬁc dissemination in Central
Asia and Eastern Europe. For example, according to the
report of HPV Information Centre (2017), no data on the
epidemiology of HPV infection are available in Kazakhstan
(which is a Central Asian country), and only a few articles on
the epidemiology of HPV infection in Kazakhstan were
published in international peer-reviewed journals and sev-
eral articles in local medical journals [53]. +e authors’
ﬁndings demonstrated that 43.6% of the patients attending
gynecologic clinic were HPV positive. +e most prevalent
types detected were HPV16 (18.4%) and HPV18 (9.22%),
followed by HPV types 33, 51, and 52 (nearly 5% each) [53].
+e prevalence of HPV infection among Africans is
higher than in the European population with 26.3% in
Nigeria, 47.9% in Guinea, 41% in South Africa, and 38.8–
42.3% in Kenya [54, 55]. Possibly high prevalence of HPV
among women in sub-Saharan African countries is more
prominent due to high exposure of human immunodeﬁciency
virus (HIV) in the country, and cervical cancer may become
epidemic if cervical cancer knowledge is not increased and the
barriers for early screening services will still exist [56].
Other studies highlighted that some special populations
have a higher risk of acquiring HPV infection. A study in-
vestigated the prevalence of HPV infection among the ado-
lescent population in Uganda has shown signiﬁcantly high
distribution of high-risk HPV types (16, 18, 31, 52, and 58),
which is 51.4% [57]. +e reasons for such high prevalence
were explained by sexual behavior, which includes early age of
sexual debut and multiple sexual partners. +ose factors put
young women at higher risk of HPV infection [50].
With the development of highly sensitive HPV DNA
testing, studies have conﬁrmed that most cervical cancer
specimens have detectable HPV DNA, and greater than 90%
contain DNA for HPV16, 18, 31, 33, 39, 45, 52, or 58 [7]. It
should be noted that women who develop cervical cancer
have often had the same type of high-risk HPV detected in
cervical specimens 3 to 5 years prior to their cancer in-
cidence. Unfortunately, HPV genotyping can only detect
current infection; therefore, we are not able to understand
when in the lifetime HPV has had a carcinogenic eﬀect [58].
Some investigators have identiﬁed regional diﬀerences in
the prevalence of squamous cell carcinoma linked to HPV
infection. In a meta-analysis of 85 studies, which included
10,058 women with cervical cancer, HPV16 prevalence
predominated in squamous cell carcinoma, ranging from
46% in Asia to 63% in North America. +e second most
prevalent type was HPV18, found in 10–14% of squamous
cell carcinoma specimens.+e frequency of adenocarcinoma
among all invasive cervical cancers also remains signiﬁcant.
It ranges from 4% in Africa to 32% in North America. As
expected, high-risk HPV type 18 was found to be dominant
in adenocarcinoma cases with a prevalence that ranges from
37% to 41%. +e next most common HPV types are type 16
and type 45, which were found in 26–36% and 5–7% of
samples, respectively [50]. According to the meta-analysis
that included 133 studies and 14,595 women, combination of
HPV16 and 18 contributes to 74–77% of squamous cell
carcinoma in Europe and North America, and 65–70% of
squamous cell carcinoma in Africa, Asia, and South/Central
America [50]. While data from meta-analyses are limited by
their reliance on the HPV DNA testing methods of each
individual study, multiple studies collecting samples from
large cohorts have conﬁrmed the presence of the same HPV
types in invasive cervical cancer specimens.
Several international studies investigated the prevalence
of HPV types in invasive cervical cancer specimens. One of
those studies explored the most prevalent types in 1918
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women with cervical cancer. For that purpose, cervical
cancer cells were directly tested for HPV types and the
researchers found the following HPV types to be the most
prevalent: HPV16, 18, 45, 31, 33, 52, 58, and 35 [59].
Similarly, an international study conducted in 38 countries
tested invasive cervical cancer paraﬃn block samples from
10,575 women for the presence of certain HPV types. +e
researchers found HPV DNA in 8977 of the samples, which
comprise 85% of all specimens. HPV16 or 18 was detected in
71%, and types 31, 33, 35, 45, 52, and 58 were detected in an
additional 20% of the HPV-positive samples.
Having a high incidence and mortality from cervical
cancer makes the screening program very important. En-
hancing public awareness of underlying causal factors is a
high priority for developing an appropriate cancer control
and prevention program.
7. Cervical Cancer Screening
It is well known that cervical cancer screening can reduce
cervical cancer incidence and mortality [60]. Cervical cancer
screening strategies are diﬀerent between countries. Some
countries have population-based programs, whereby women in
the target population are individually identiﬁed and invited to
attend the screening. In opportunistic screening, invitations
depend on the individual’s decision or on encounters with
healthcare providers. Organized cervical screening programs
may achieve high participation at regular intervals with equal
access, and high-quality standards for diagnosis, thus potentially
more eﬀective than opportunistic screening [61, 62]. Examples of
organized programs for cervical cancer screenings exist in high-
income countries such as the United Kingdom, Australia,
Canada, Finland, the Netherlands, and Singapore. On the other
hand, Eastern European countries have an opportunistic
screening with lower-screening coverage and lower-immuni-
zation coverage and show high cervical cancer incidence and
mortality rates [42]. In most of the Central Asian countries, the
Caucasus region, the Russian Federation, and the Western
countries of the former SovietUnion, cervical cancer screening is
mainly opportunistic and characterized by cytology testing,
using Romanowsky staining and generally low or unreported
coverage [63]. Nevertheless, cervical cancer screening contrib-
utes to a decrease in cervical cancer incidence andmortality [64].
HPV vaccine was introduced later. Developed countries
have accomplished reduction of cervical cancer incidence
and mortality during the last 40 years due to the in-
troduction of cytological smear screening [65]. For instance,
since the introduction of the Pap smear cytology testing in
the 1950s and 1960s, cervical cancer incidence and mortality
have declined in the United States with organized cervical
cancer screening programs and screening rates of 83% [66].
In the Northern European countries, an organized screening
program was established in the 1960s and their eﬀects on
cervical cancer incidence and mortality have been accurately
investigated [62]. However, in the greater part of Europe,
evaluation systems are insuﬃcient and nonstandard.
At the same time, cervical cancer prevalence remains at a
high level in developing countries of Central and South-East
Asia, Africa, and Eastern Europe, where cervical cancer
screening programs are not properly implemented due to a
variety of reasons (socioeconomic, geographic, etc.). Pop-
ulation coverage by screening program in developing
countries ranges between 6 and 8% [67]. In recent years,
international recommendations for screening have been
developed to include HPV testing, where available [68].
Despite marked advances in knowledge about cervical
cancer and eﬀective screening, cervical cancer screening
programs have variable eﬃcacy depending on availability of
resources, implementation strategies, quality of laboratory
and pathology testing, and community awareness [69].
Eﬀective cytological screening of cervical specimens and
HPV genotyping require materials and specialists that are
complicated and expensive for many low-income countries
[70]. Even in developed countries with advanced healthcare
systems and long-standing cervical cancer screening mo-
dalities, population coverage is not perfect [71].
+ere is also discrepancy in the frequency of the
screening tests among countries and age groups [72]. In
developed countries like England and the USA, screening is
scheduled every 3 years for women aged 21–29; starting from
30 years old until 65 years old, the screening tests are
recommended for every 5 years [73–75]. Results of the
population-based survey of adults aged 50–70 in England
suggest that although awareness of the purpose of early
detection screening is high, awareness that screening can
prevent cancer is low across all demographic groups [74].
In most of the developing countries of Africa, Central
Asia, South-East Asia, Eastern Europe, screening is sched-
uled every 5 years or even rarer [72, 76]. However, there are
several exclusions. For instance, in Kyrgyzstan, republic of
Central Asia, there is no cervical cancer screening program
at all [63]. In South Africa, a national cervical screening
policy was formulated in 2000 and allowed for three free
cervical smear tests, conducted at 10-year intervals from the
age of 30 years [72]. +is policy has been implemented in
some areas; however, there is currently no population-wide
screening program in South Africa.
Although the recommended screening modalities for
cervical cancer have contributed to a reduction in cervical
cancer incidence and mortality due to cervical cancer, the
beneﬁts of cervical cancer screening are yet to be fully re-
alized in countries with poorly organized screening pro-
grams for women at risk. +e updated WHO
recommendations for cervical cancer screening and pre-
vention are summarized in Table 1 [21].
It is also noteworthy that even in countries with orga-
nized screening services, these beneﬁts are not maximized in
underserved, uninsured, and underrepresented populations
due to factors such as cost, access problems, anxiety, dis-
comfort with the screening procedure, and fear of cancer or
poor health literacy, all of which contribute to poor out-
comes for cervical cancer [77].
Incorporation of HPV testing into cervical cancer
screening strategies has the potential to allow both increased
disease detection and increased length of screening intervals
(decreasing harms such as psychosocial impact of screening
positive, additional clinical visits and procedures, and
treatment of lesions destined to resolve).
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8. HPV Vaccination
Statistical data from the recent years show that utilization of
HPV vaccines is very eﬀective for preventing infection and
disease related to the speciﬁc HPV genotypes [78]. Vacci-
nation programs have been very successfully implemented
in many countries all over the world [78, 79].
+ere are three commercially prophylactic vaccines
available; these are Cervarix (a bivalent vaccine against HPV16
and HPV18), Gardasil (a tetravalent against HPV6, 11, 16, and
18), and Gardasil 9 (9-valent vaccine against HPV6, 11, 16, 18,
31, 33, 45, 52, and 58).+ey are noninfectious subunit vaccines
containing viral-like particles (VLP) derived from the assembly
of the recombinant expression of L1major capsid protein of the
HPV in yeast (Gardasil) and in insect cells (Cervarix). Ad-
ministration of the vaccine is carried out by intramuscular
injection with three doses of prime/boost series over a 6-month
period. Early analysis shows that even a single dose can reduce
infection and is eﬀective in preventing the persistent incidence
of infection and premalignant neoplasia [80].+e exceptionally
strong and lasting antibody response has been well docu-
mented; for example, the 100% seroconversion rate in young
healthy women, preadolescent boys, and girls with antibody
response remains stable for over a decade [81]. +e exact
molecular mechanism however is still elusive in humans as
HPV hosting organism, and presently, there is no human
model to study the mechanism except on transgenic mouse
models and xenograft models [38]. Screening remains to be the
only form of prevention for 2 to 3 generations of women
beyond the adolescent target age for vaccination [82].
At the present time, we have an abundance of evidence
from multiple countries, with a diﬀerent level of HPV vac-
cination coverage and implementation strategies that show
the vaccines are eﬀective [78]. In developing countries with
long-standing screening programs, catch-up vaccination
cohorts and established registration have demonstrated re-
ductions in the diagnosis of CIN in screening women due to
vaccination [78]. For example, the researchers from Scotland
show a reduction of low- and high-grade CIN associated with
high uptake of the HPV bivalent vaccine at the population
level [83]. Results from one of the recent studies from Japan
demonstrated that women aged 20–24 years who received
HPV vaccination had signiﬁcantly lower rates of abnormal
cervical cytology results when compared to those who did not
receive the vaccine [79]. An Australian study found that
vaccination employing tetravalent HPV vaccine helps to re-
duce cases of HSIL and LSIL in females [84]. Research
ﬁndings from Canada suggest that the HPV vaccination was
moderately eﬀective in preventing HSIL among adolescents
but far less eﬀective in the older age groups, especially among
those with a history of abnormal cytology [85].
Taking into consideration the present eﬀorts to increase
HPV vaccinations for primary cervical cancer prevention,
early detection of precancerous cervical lesions through
screening remains to be very important in order to timely
diagnose and reduce cervical cancer incidence and mortality.
+is is especially true in low-income regions where HPV
vaccination has not yet implemented and supported at the
governmental level [86]. Developed countries, with well-
established cervical cancer screening programs, have achieved
an impressive reduction in cervical cancer incidence and
mortality, while developing countries with lack of HPV
vaccination and/or worse modalities of screening programs
still have a high level of adverse outcomes [87]. +ese dis-
crepancies in HPV vaccination envelopment could explain
the diﬀerences in incidence, prevalence, and mortality linked
to cervical cancer in diﬀerent countries in the world.
HPV vaccination for the prevention of high-risk HPV
types is expected to reduce cervical cancer burden [88].
Supporting HPV vaccines’ eﬀectiveness against cervical
Table 1: WHO recommendations on cervical cancer screening and prevention in the low- and middle-income countries.
Primary prevention: vaccination Secondary prevention: screening
Methods
Inclusion of HPV vaccine in the national immunization
schedule:
(i) Bivalent
(ii) Tetravalent
(i) Cervical cytology (conventional Pap
smear and liquid-based)
(ii) Visual inspection with acetic acid
(VIA)/visual inspection with Lugol’s iodine
(VILI)
(iii) HPV testing for high-risk HPV types
(i.e., types 16, 18,31, 33, 45, and 58)
Target age group (years) and
gender
Girls 9–14 years
old Girls over 15 years old Women 30–49 years old
Frequency and intervals
2 doses 3 doses (i) Once in life time
(ii) Once in 10 years
(iii) Once in 5 years
(a) VIA/cytology every 3- to 5-year
interval;
(b) HPV testing minimum every 5-year
interval
6-month
interval
Bivalent: 0, 1, 6 months; tetravalent: 0, 2, 6
months
Programmatic consideration School-based delivery strategy
(i) Organized program
(ii) Unorganized/opportunistic/sporadic
initiatives
(a) Screen-and-treat approach
(b) Screen-diagnose-treat approach
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cancer is diﬃcult due to the long period between initial in-
fection and cancer development. Surrogate markers therefore
have been proposed to determine vaccines’ eﬀectiveness on a
shorter term, such as population-based continuous moni-
toring of high-grade precursor lesions such as CIN3 [89].
Statistics received from studies that covered large cohorts of
women after implementation of Cervarix or Gardasil have
shown that both vaccines are eﬀective in order to reduce the
frequency of precancerous lesions associated with the vaccine
genotypes [90]. On the other hand, even the nonavalent
Gardasil vaccine cannot prevent all cervical cancer cases due
to type speciﬁcity and time of implementation.
+ere are also apparent limitations and the public health
challenges in attempting to implement HPV vaccination
programs. +ese limitations and challenges include the
vaccine’s type speciﬁcity, required to be given prior to ex-
posure, the three-dose schedule, ethical issues in targeting
age group of early adolescence, and potential communica-
tion challenges around HPV being a sexually transmitted
infection [78]. +erefore, large groups of women in ad-
vanced age who have not received vaccination are still under
the risk of cervical cancer development. Furthermore, HPV
screening and vaccination being complementary preventive
options are often implemented as separate and non-
coordinated public health programs. +erefore, to address
this inaccuracy, the recently created “HPV FASTER” pro-
tocols aim at combining both strategies with the purpose of
accelerating the reduction of cervical cancer incidence and
mortality, making the programs both cost-eﬀective and
sustainable [91].+e proposal of “HPV FASTER” protocol is
to oﬀer HPV vaccination to women in a broad age range of 9
to 45 years irrespective of HPV status.
In developing countries, reduction of cervical cancer
incidence and mortality could be achieved only with gov-
ernmental guidance by the implementation of sustainable
and eﬀective screening and vaccination programs.
9. Conclusion
Cervical cancer is associated with considerable morbidity
and mortality all over the world. It is well known that one of
the main causative agents for cervical cancer is high-risk
HPV strains, and this type of malignancy is preventable.
High incidence of cervical cancer with considerable mor-
tality is an evidence of HPV infection abundance with the
absence of the HPV screening and low public awareness of
the problem. Substantial incidence and mortality from
cervical cancer make the screening program very important.
Enhancing public awareness of underlying causal factors is a
priority that should be emphasized for prevention programs.
Incorporation of HPV testing into screening strategies has a
high potential to decrease morbidity and mortality from
cervical cancer. +e knowledge of HPV prevalence and type
distribution could contribute to the successful vaccination
program implementation. +e educational health pro-
motion projects for the population should be provided to
reinforce the knowledge and conversance of this public
health problem. From the review given here, it is clear that
the HPV screening along with the vaccination program
should be implemented and supported at a governmental
level in developing countries with high incidence and
mortality of cervical cancer.
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